The role of parkin in Parkinson's disease;A parkin szerepe a Parkinson-kórban

Neuropsychopharmacologia Hungarica

Volumn 16, Issue 2, 2014, Pages 67-76

  Miklya, Ildikó ^a   Göltl, Patrícia ^a   Hafenscher, Florencia ^a   Pencz, Noémi ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Mitochondrial dysfunction; Mutation; Parkin; Parkinson's disease; Protein aggregation

Indexed keywords

ALPHA SYNUCLEIN; PARKIN;

DEGENERATIVE DISEASE; ENZYME ACTIVITY; GENE MUTATION; HUMAN; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; REGULATORY MECHANISM; REVIEW;

ALPHA-SYNUCLEIN; ANIMALS; DOPAMINE; DOPAMINERGIC NEURONS; GENE-ENVIRONMENT INTERACTION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAINIC ACID; MITOCHONDRIA; ONCOGENE PROTEINS; OXIDATIVE STRESS; PARKINSON DISEASE; POINT MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84903708301     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., Halliwell, B. (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem, 69: 1196-1203.
2. Berman, S. B., Hastings, T. G. (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neureochem, 73: 1127-1137.
3. Bindoff, L. A., Birch-Machin, M. A., Cartlidge, N. E., Parker Jr., W. D., Turnbull, D. M. (1991) Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci, 104: 203-208.
4. Blesa, J., Phani, S., Jackson-Lewis, V., Przedborski, S. (2012) Classic and new animal models of Parkinson's disease. J Biomed Biotech, 1-10.
5. Canet-Aviles, R. M., Wilson, M. A., Miller, D. W., Ahmad, R., McLendon, C., Bandyopadhyay, S., Baptista, M. J., Ringe, D., Petsko, G. A., Cookson, M. R. (2004) The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Nat Acad Sci, USA 101: 9103-9108.
6. Chance, B., Sies, H., Boveris, A. (1979) Hydrogenperoxide metabolism in mammalian organs. Physiol Rev, 59: 527-605.
7. Chung, K. K., Thomas, B., Li, X., Pletnikova, O., Troncoso, J. C., Marsh, L., DSawson, V. L., Dawson, T. M. (2004) S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science, 304: 1328-1331.
8. Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P., Marsden, C. D. (1989) Basal lipid peroxidation in substatia nigra is increased in Parkinson's disease. J Neurochem, 52: 381-389.
9. Ding W. X., Yin X. M. (2012) Mitophagy: mechanisms, pathophysiological roles, and analysis. Biol Biochem, 393: 547-564.
10. Ding, W. X., Ni, H. M., Lioa, Y., Chen, X., Stolz, D. B., Dorn Jr., G. W., Yin, X. M. (2010) Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. J Biol Chem, 285: 27879-27910.
11. Floor, E., Wetzel, M. G. (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophylhydrasine assay. J Neurochem, 70: 268-275.
12. Gao, H. M., Hong, J. S. (2011) Gene-environment interactions: Key to unraveling the mystery of Parkinson's disease. Prog Neurobiol, 94: 1-19.
13. Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y., Minakami, S. (1990) 1-Methyl-4-phenylpyridinium (MPP+) induces NADHdependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun, 170: 1049-1055.
14. Hastings, T. G. (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem, 64: 919-924.
15. Hattori, N., Kitada, T., Matsumine, H., Asakawa, S., Yamamura Y., Yoshino, H., Kobayashi, T., Yokochi, M., Wang, M., Yoritaka A., Kondo T., Kuzuhara, S., Nakamura, S., Shimizu N., Mizuno, Y. (1998) Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol, 44: 935-941.
16. Hauser, D. N., Hastings, T. G. (2013) Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism. Neurobiol Dis, 51: 35-42.
17. Haywood, A. F. M., Staveley, B. E. (2004) Parkin counteracts symptoms in Drosophila model of Parkinson's disease. BMC, 5: 14.
18. Heikkila, R. E., Hess, A., Duvoisin, R. C. (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine in mice. Science, 224: 1451-1453.
19. Herrero-Mendez, A., Almeida, A., Fernandez, E., Maestre, C., Moncada, S., Bolanos, J. P. (2009) The bioenergetic and antioxidant status of neurons is controlled by continuous of a key glycolytic enzyme by APC/C-Cdh1. Nat Cell Biol, 11: 747-752.
20. Kahle, P. J., Haass, C. (2004) How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep, 5: 681-685.
21. Kalia, S. K., Lee, S., Smith, P. D., Liu, L., Crocker, S. J., Thorarinsdottir, T. E., Glover, J. R., Fon, E. A., Park, D. S., Lozano, A. M. (2004) BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron, 44: 931-945.
22. Krige, D., Caroll, M. T., Cooper, J. M., Marsden, C. D., Schapira, A. H. (1992) Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Group. Ann Neurol, 32: 782-788.
23. Langston, J. W., Ballard, P., Tetrud, J. W., Irwin. I. (1983) Chronic Parkinsonism in humans due to a product of meperidineanalog synthesis. Science, 219: 979-980.
24. Langston, J. W., Forno. L. S., Robert, C. S., Irwin I. (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res, 292: 390-394.
25. Lavoi, M. J., Ostaszewski, B. L., Weihofen, A., Sclossmacher, M. G., Selkoe, D. J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat Med, 11: 1214-1221.
26. Li, N., Ragheb, K., Lawler, G., Sturgis, J., Rajwa, B., Melendez, J. A., Robinson, J. P. (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem, 278: 8516-8525.
27. Li, M., Schönberg, A., Schaefer, M., Schroeder, R., Nashidze, I., Stoneking, M. (2010) Detecting heteroplasmy from highthroughput sequencing of complete human mitochondrial DNA genomes. Am J Hum Genet, 87: 237-249.
28. Lucking, C. B., Durr, A., Bonifati, V., Vaughan, J., De, M. G., Gasser, T., Harhangi, B. S., Meco, G., Denefle, P., Wood, N. W., Aqid, Y., Brice, A. (2000) Association between early-onset Parkinson's disease and mutation in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl. Med, 342: 1560-1567.
29. Luoma, P., Melberg, A. Rinne, J. O., Kaukonen, J. A., Nupponen, N. N., Chalmers, R. M., Oldfors, A., Rautakorpi, I., Peltonen, L., Majamaa, K., Somer, H., Suomalainen, A. (2004) Parkionsonism, premature menopause, and mitochondrial DNA polymerase gamma mutation: clinical and molecular genetic study. Lancet, 364: 875-882.
30. Mastroberardino, P. G., Hoffman, E. K., Horowitz, M. P., Betarbet, R., Taylor, G., Cheng, D., Na, H. M., Gutekunst, C. A., Gearing, M., Trojanowski, J. Q., Anderson, M., Chu, C. T., Peng, J., Greenamyre, J. T. (2009) A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis, 34: 417-431.
31. Mata, I. F., Lockhart, P. J., Farrer, M. J. (2004) Parkin genetics: One model for Parkinson's disease. Hum Mol Genet, 1: R127-R133.
32. McNaught, K. S., Mytilineou, C., Jnobaptiste, R., Yabut, J., Shshidharan, P., Jennert, P., Olanow, C. W. (2002) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem, 81: 301-306.
33. Mizuno, Y., Hattori, N., Mori, H., Suzuki T., Tanaka, K. (2001) Parkin and Parkinson's disease. Curr Opin Neurol 14: 477-482.
34. Moore. D. J., Dawson, V. L., Dawson, T. M. (2003) Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloides. Neuromolecular Med, 4: 95-108.
35. Moore, D. J., West, A. B., Dawson, V. L., Dawson, T. M. (2005) Molecular patophysiology of Parkinson's disease. Ann Rev Neurosci, 28: 57-87.
36. Moore, D. J., Dawson, T. M. (2008) Value of genetic models in understanding the cause and mechanism of Parkinson's Disease. Curr Neurol Neurosci Rep, 8: 288-296.
37. Nagakubo, D., Taira, T., Kitaura, H., Ikeda, M., Tamai, K., Iguchi-Ariga, S. M., Ariga, H. (1997) DJ-1, a novel oncogene which transforms mouse NIH3Z3 cells in cooperation with ras. Biochem Biophys Res Commun, 231: 509-513.
38. Parker Jr., W. D., Parks, J. K., Swerdlow, R. H. (2008) Complex I deficiency in Parkinson's disease frontal cortex. Brain Res, 1189: 215-218.
39. Petrucelli, L., Dawson, T. M. (2004) Mechanism of neurodegenerative disease: Role of the ubiquitin proteasome system. Ann Med, 36: 315-320.
40. Poole, A. C., Thomas, R. E., Yu, S., Vincow, E. S., Pallank, L. (2010) The mitochondrial fusion promoting factor mitofusin is a substrate of the PINK1/parkin pathway. Plos ONE, 5(4): e10054.
41. Rabinovic, A. D., Hastings, T: G. (1998) Role of endogenous glutathione in the oxidation of dopamine. J Neurochem, 71: 2071-2078.
42. Rana, A., Rera, M., Walker, D. W. (2012) Parkin overexpression during aging reduces proteotoxicity, alter mitochondrial dynamics, and extends lifespan. Proc Nat Acad Sci USA, 110: 8638-8643.
43. Reitzer, L. J., Wice, B. M., Kennell, D. (1979) Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cell. J Biol Chem, 254: 2669-2676.
44. Rosen, K. M., Veereshwarayya, V., Moussa, C. E., Fu, Q., Goldberg, M. S., Schlossmacher, M. G., Shen, J., Querfurth, H. W. (2006) Parkin protects against mitochondrial toxins and betaamyloid accumulation in skeletal muscle cells. J Biol Chem, 281: 12809-12816.
45. Schapira, A. H., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., Marsden, C. D. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet, 1: 1269.
46. Sherer, T. B., Betarbet, R., Testa, C. M., Seo, B. B., Richardson, J. R., Kim, J. H., Miller, G. W., Yagi, T., Matsuno-Yagi, A., Greenamyre, J. T. (2003) Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci, 23: 10756-10764.
47. Shimura, H., Hattori, N., Kubo, S., Yoshikawa, M., Kitada, T., Matsumine, H., Asakawa, S., Monoshima, S., Yamamura, Y., Shimizu, N., Mizuno, Y. (1999) Immunhistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol, 45: 668-672.
48. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., Suzuki, T. (2000) Familial Parkinson disease gene product, parkin is a ubiquitin-protein ligase. Nat Genet, 25: 302-305.
49. Smith, C. V., Jones, P. D., Guenthner, T. M., Lash, L. H., Lauterburg, B. H. (1996) Compartmentation of glutathione: implications for the study of toxicity and disease. Toxico Appl Pharmacol, 140: 1-12.
50. Sofic, E., Riederer, P., Heinsen, H., Beckmann, H., Reynolds, G. P., Hebenstreit, G., Youdim, M. B. (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm, 74: 199-205.
51. Sonderheimer, N., Glatz, C. E., Tirone, J. E., Deardoff, M. A., Krieger, A. M., Hakonarson, H. (2011) Neutral mitochondrial heteroplasmy and the influence of aging. Hum Mol Genet, 20: 1653-1659.
52. Syed, F. A., Zbigniew, K. B., Syed, Z. I. (2011) Molecular aspects of dopaminergic neurodegeneration: gene-environment interaction in parkin dysfunction. Int J Environ Res Public Health, 8: 4702-4713.
53. Tait, S. W. G., Green, D. R. (2012) Mitochondria and cell signaling. J Cell Sci, 125: 807-815.
54. Tanner, C. M., Kamel, F., Ross, G. W., Hoppin, J. A., Goldman, S. M., Korell, M., Marras, C., Bhudhikanok, G. S., Kasten, M., Chade, A. R., Comyns, K., Richards, M. B., Meng, C., Priestley, B., Fernandez, H. H., Cambi, F., Umbach, D. M., Blair, A., Sandler, D. P., Langston, J. W. (2011) Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect, 119: 866-872.
55. Yamamoto, A., Friedlein, A., Imai, Y., Takahashi, R., Kahle, P. J., Haass, C. (2005) Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J Biol Chem, 280: 3390-3399.
56. Van der Goot, A. T., Zhu, W., Vázquez-Manrique, R. P., Seinstra, R. I., Dettmer, K., Michels, H., Farina, F., Krijnen, J., Melki, R., Buijman, R. C., Silva, M. R., Thijssen, K. L., Kema, I. P., Neri, C., Oefner, P. J., Nollen E. A. A. (2012) Delaying aging and the aging-associated decleine in protein homeostasis by inhibition of tryptophan degeneration. Proc Nat Acad Sci USA, 109: 14912-14917.
57. Van Laar, V. S., (2008) Protemic analysis of rat brain mitochondria following exposure to dopamine quinine: implications for Parkinson disease. Neurobiol Dis, 29: 477-489.
58. Wilson, M. A., Collins, J. L., Hod, Y., Ringe, D., Petsko, G. A. (2003) The 1. 1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc Nat Acad Sci USA, 100: 9256-9261.
59. Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L., Eklund, A. C., Zhang-James, Y., Kim, P. D., Hauser, M. A., Grünblatt, E., Moran, L. B., Mandel, S. A., Riederer, P., Miller, R. M., Federoff, H. J., Wüllner, U., Papapetropoulos, S., Youdim, M. B., Cantuti-Castelverti, I., Young, A. B., Vance, J. M., Davis, R. L., Hedreen, J. C., Adler, C. H., Beach, T. G., Graeber, M. B., Middleton, F. A., Rochet, J. C., Scherzer, C. R. (2010) PGC-1 alpha, a potential therapeutic target for early intervention in Parkinson's disease. Global PD Gene Expression (GPEX) Consortium. Sci Transl Med, 2(52ra73).
60. Zivani, E., Tao, R. N., Whitworth, A. J. (2010) Drosphila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc Nat Acad Sci USA, 107: 5018-5023.